Education
About Us
Working with TipRanks
Follow Us
BioStem Technologies Inc (BSEM)
OTHER OTC:BSEM
RESEARCH TOOLSreports
Top Page
BioStem Technologies
(OTC:BSEM)
Rating:79Outperform
Price Target:
$14.50
▲(29.23%Upside)
BioStem Technologies (BSEM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$183.32M
Dividend YieldN/A
Average Volume (3M)63.84K
Price to Earnings (P/E)7.6
Beta (1Y)1.90
Revenue Growth473.06%
EPS GrowthN/A
CountryUS
Employees2
SectorHealthcare
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)0.27
Shares Outstanding16,338,436
10 Day Avg. Volume36,569
30 Day Avg. Volume63,835
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)6.53
Price to Sales (P/S)0.00
P/FCF Ratio10.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BioStem Technologies Business Overview & Revenue Model
Company DescriptionBioStem Technologies (BSEM) is a biotechnology company specializing in the development and commercialization of regenerative medicine technologies. The company operates within the life sciences sector, focusing on innovative solutions that harness the power of stem cells to repair and regenerate damaged tissues. BioStem Technologies provides a range of products and services, including human allografts, amniotic tissue products, and other advanced wound care solutions designed to improve patient outcomes and support tissue healing.
How the Company Makes MoneyBioStem Technologies generates revenue through the sale of its proprietary regenerative medicine products, which include human allografts and amniotic tissue products used in various medical applications such as orthopedics, wound care, and ophthalmology. The company collaborates with healthcare providers, hospitals, and clinics to distribute its products and expand its market reach. Additionally, BioStem Technologies may engage in strategic partnerships and licensing agreements with other biotech firms to enhance its product offerings and leverage new market opportunities, contributing to its overall revenue growth.
BioStem Technologies Earnings Call Summary
Earnings Call Date:May 12, 2025
(Q1-2025)
| % Change Since: -26.18%|
Next Earnings Date:Aug 26, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth and profitability achievements for BioStem Technologies, underscoring the company's operational strength and financial resilience. Despite challenges such as increased operating expenses and market uncertainty due to LCD delays, the company remains on a positive trajectory with ongoing clinical trials and strategic initiatives. The sentiment is bolstered by strong cash reserves and gross profit margins, although the pending SEC review for NASDAQ uplisting presents a potential hurdle.Q1-2025 Updates
Positive Updates
Record Revenue Growth
BioStem Technologies delivered its strongest first quarter revenue in company history, with revenue increasing 73% year-over-year to $72.5 million.
Profitability Achievement
Reported GAAP net income of $4.5 million or $0.27 per share, marking the fifth consecutive quarter of profitability.
Strong Financial Position
BioStem ended the quarter with $26.7 million in cash, an increase from $22.8 million in Q4 2024.
Gross Profit Margin Improvement
Gross profit was $71.7 million, or 99% of net revenue, compared to 95% in Q1 2024, reflecting product mix benefits and scale efficiencies.
Clinical Trial Progress
Initiated a new clinical trial for BioREtain Amnion Chorion and received IRB approval. Progress is being made in existing trials with data readouts expected by mid to late 2025.
Negative Updates
Operating Expense Increase
Operating expenses for Q1 were $66.4 million, up from $35.1 million in the prior year period, due to investments in headcount, legal fees, and higher R&D costs.
Impact of LCD Uncertainty
The delay in LCD implementation created headwinds across the chronic wound care market, impacting sequential quarterly growth.
Pending SEC Review for NASDAQ Uplisting
BioStem is undergoing an SEC review process related to its planned uplisting to NASDAQ, which may impact financial statement presentation.
Company Guidance
In the first quarter of 2025, BioStem Technologies reported a record-breaking revenue of $72.5 million, marking a significant 73% increase year-over-year and achieving profitability for the fifth consecutive quarter. The company's GAAP net income was $4.5 million, equivalent to $0.27 per share, and they reported an adjusted EBITDA of $7.8 million. The quarter ended with BioStem holding $26.7 million in cash, up from $22.8 million in the previous quarter. Despite challenges posed by the LCD's uncertainty, which affected sequential growth, BioStem's strategy to transition customers to VENDAJE AC is expected to reduce SG&A costs, as the product does not carry licensing fees. The company's partnership with Venture Medical is expanding, with over 150 sales reps and plans to add 1,099 more, alongside a new 40-person direct sales team. BioStem's focus on clinical trials continues, with three active programs, including a new trial for venous leg ulcers. Additionally, they are advancing in their efforts to up-list to NASDAQ, a move expected to enhance their shareholder base and market visibility.BioStem Technologies Financial Statement Overview
Summary
BioStem Technologies is showing signs of financial recovery and strength with improved profitability and cash flow in the TTM period. While the balance sheet now shows positive equity, historical losses and a low equity ratio indicate potential risks. The company appears to be on a positive trajectory, but continued vigilance is necessary to maintain stability.Income Statement
BioStem Technologies shows a strong improvement in profitability with a gross profit margin of 94.8% and a net profit margin of 7.1% in TTM, indicating efficient cost management. Revenue growth is robust, with an increase from previous annual periods. However, past years show a history of losses, which could be a concern if not fully addressed.85
Very Positive
Balance Sheet
The company's balance sheet reflects improved equity with a positive stockholders' equity of $22.8 million in TTM, after years of negative equity. The debt-to-equity ratio is 0.20, indicating low leverage. However, the equity ratio is only 21.9%, suggesting a relatively low proportion of equity financing.60
Neutral
Cash Flow
Free cash flow has turned positive with a significant growth rate in TTM, which is a favorable sign for liquidity. The operating cash flow to net income ratio of 1.00 suggests solid cash earnings. Despite past negative cash flows, current performance shows improved cash management.75
Positive
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 210.39M | 16.69M | 6.88M | 4.34M | 2.52M | 2.63M | Gross Profit |
| 199.38M | 15.42M | 5.99M | 2.87M | 1.25M | 1.31M | EBIT |
| 19.89M | -7.78M | -4.68M | -1.61M | -1.84M | -5.73M | EBITDA |
| 20.52M | -7.55M | -6.52M | -602.00K | -1.59M | -5.38M | Net Income Common Stockholders |
| 14.88M | -8.48M | -7.07M | -1.45M | -2.39M | -6.38M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 174.01K | 239.41K | 772.14K | 340.33K | 100.70K | 140.74K | Total Assets |
| 214.18K | 14.56M | 3.47M | 2.67M | 2.67M | 3.15M | Total Debt |
| 68.50K | 4.77M | 5.09M | 4.83M | 5.63M | 5.11M | Net Debt |
| 54.96K | 4.53M | 4.32M | 4.49M | 5.52M | 4.97M | Total Liabilities |
| 68.50K | 15.90M | 7.42M | 8.47M | 8.30M | 7.09M | Stockholders Equity |
| 145.68K | -1.34M | -4.08M | -5.96M | -5.80M | -4.09M |
| Cash Flow | Free Cash Flow | ||||
| 14.61M | -3.60M | -2.11M | -152.29K | -585.25K | -979.38K | Operating Cash Flow |
| 14.91M | -3.50M | -1.64M | -109.44K | -581.57K | -845.79K | Investing Cash Flow |
| -1.55M | -210.33K | -469.48K | -7.85K | -3.69K | 45.41K | Financing Cash Flow |
| 1.14M | 3.18M | 573.12K | 357.42K | 541.52K | -235.03K |
BioStem Technologies Technical Analysis
Negative
11.22
Price Trends
11.59
Negative
12.87
Negative
13.12
Negative
Market Momentum
-0.31
Positive
40.62
Neutral
28.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSEM, the sentiment is Negative. The current price of 11.22 is below the 20-day moving average (MA) of 12.76, below the 50-day MA of 11.59, and below the 200-day MA of 13.12, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 40.62 is Neutral, neither overbought nor oversold. The STOCH value of 28.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BSEM.
BioStem Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $183.32M | 7.60 | 122.26% | ― | 473.06% | ― | |
53 Neutral | $5.22B | 3.32 | -45.04% | 2.83% | 16.81% | -0.27% | |
51 Neutral | $137.46M | 87.50 | -24.22% | ― | -23.40% | 17.80% | |
49 Neutral | $174.65M | ― | -52.64% | ― | 82.38% | 3.63% | |
46 Neutral | $306.46M | ― | 123.38% | ― | 10.49% | 47.31% | |
36 Underperform | $133.66M | ― | -244.16% | ― | ― | 77.12% | |
28 Underperform | $48.54M | ― | -41.96% | ― | ― | 72.12% |
* Healthcare Sector Average
Performance Comparison
BSEM
BioStem Technologies
11.22
3.37
42.93%
CGEN
Compugen
1.47
-0.72
-32.88%
PRQR
ProQR
1.66
-0.32
-16.16%
HURA
TuHURA Biosciences
3.06
-6.43
-67.76%
ADCT
ADC Therapeutics
3.09
-0.22
-6.65%
KLRS
Kalaris Therapeutics
2.90
-14.25
-83.09%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.